Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRd-based Regimen Combined With CART-ASCT-CART2 in Newly Diagnosed Multiple Myeloma
NCT05850286Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Apr 2023; status: active, not recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05850286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850286.